Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human

RA Halpin, EH Ulm, AE Till, PH Kari, KP Vyas, DB Hunninghake and DE Duggan

Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19488.

Lovastatin is a prodrug lactone whose open-chain 3,5-dihydroxy acid is a potent, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis. The compound undergoes extensive and complex metabolism in animals and humans, with the metabolites excreted predominantly in bile. Radiochromatograms of bile from three human subjects and of bile and liver homogenates from mouse, rat, and dog displayed obvious species differences. Biotransformation of lovastatin occurred by three distinct routes, namely hydrolysis of the lactone ring to yield the pharmacologically active dihydroxy acid, cytochrome P-450-mediated oxidation of the fused-ring system, and beta-oxidation of the dihydroxy acid side chain. The first two reactions occurred in all four species, but the last was observed in mouse and rat only. The P-450 reactions, hydroxylation and a novel dehydrogenation reaction, yielded a 6'- hydroxylated metabolite of the dihydroxy acid and a 6'-exomethylene derivative as major and minor metabolites, respectively, in the bile of rat and dog. Human bile, which contained predominantly polar metabolites, yielded these metabolites in similar proportions only after mild hydrolysis at pH 5.0. In mouse and rat an atypical beta- oxidation of the dihydroxy acid side chain occurred to give a pentanoic acid derivative that was observed in liver homogenates. This metabolite was subsequently conjugated with taurine and excreted in the bile. From these studies, cytochrome P-450 oxidation is the primary route of phase I metabolism for lovastatin in human and dog, but beta-oxidation plays a major metabolic role in rodents.

Volume 21, Issue 6, pp. 1003-1011, 11/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				P. Li, P. S. Callery, L.-S. Gan, and S. K. Balani Esterase Inhibition Attribute of Grapefruit Juice Leading to a New Drug Interaction Drug Metab. Dispos., July 1, 2007; 35(7): 1023 - 1031. [Abstract] [Full Text] [PDF]

				P. Li, P. S. Callery, L.-S. Gan, and S. K. Balani Esterase Inhibition by Grapefruit Juice Flavonoids Leading to a New Drug Interaction Drug Metab. Dispos., July 1, 2007; 35(7): 1203 - 1208. [Abstract] [Full Text] [PDF]

				S.-J. Reilly, E. M. O'Shea, U. Andersson, J. O'Byrne, S. E. H. Alexson, and M. C. Hunt A peroxisomal acyltransferase in mouse identifies a novel pathway for taurine conjugation of fatty acids FASEB J, January 1, 2007; 21(1): 99 - 107. [Abstract] [Full Text] [PDF]

				C. Li, R. Subramanian, S. Yu, and T. Prueksaritanont ACYL-COENZYME A FORMATION OF SIMVASTATIN IN MOUSE LIVER PREPARATIONS Drug Metab. Dispos., January 1, 2006; 34(1): 102 - 110. [Abstract] [Full Text] [PDF]

				T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu, J. H. Lin, P. G. Pearson, and T. A. Baillie Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization Drug Metab. Dispos., May 1, 2002; 30(5): 505 - 512. [Abstract] [Full Text] [PDF]

				R. Subramanian, X. Fang, and T. Prueksaritanont Structural Characterization of in Vivo Rat Glutathione Adducts and a Hydroxylated Metabolite of Simvastatin Hydroxy Acid Drug Metab. Dispos., March 1, 2002; 30(3): 225 - 230. [Abstract] [Full Text] [PDF]

				T. Prueksaritanont, B. Ma, X. Fang, R. Subramanian, J. Yu, and J. H. Lin beta -Oxidation of Simvastatin in Mouse Liver Preparations Drug Metab. Dispos., October 1, 2001; 29(10): 1251 - 1255. [Abstract] [Full Text] [PDF]

				A. E. Black, R. N. Hayes, B. D. Roth, P. Woo, and T. F. Woolf Metabolism and Excretion of Atorvastatin in Rats And Dogs Drug Metab. Dispos., August 1, 1999; 27(8): 916 - 923. [Abstract] [Full Text]

				W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L. Z. Benet, K.-Fr. Sewing, and U. Christians Comparison of Cytochrome P-450-Dependent Metabolism and Drug Interactions of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Lovastatin and Pravastatin in the Liver Drug Metab. Dispos., February 1, 1999; 27(2): 173 - 179. [Abstract] [Full Text]

				A. E. Black, M. W. Sinz, R. N. Hayes, and T. F. Woolf Metabolism and Excretion Studies in Mouse After Single and Multiple Oral Doses of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitor Atorvastatin Drug Metab. Dispos., August 1, 1998; 26(8): 755 - 763. [Abstract] [Full Text]

				M. Boberg, R. Angerbauer, W. K. Kanhai, W. Karl, A. Kern, M. Radtke, and W. Steinke Biotransformation of Cerivastatin in Mice, Rats, and Dogs in vivo Drug Metab. Dispos., July 1, 1998; 26(7): 640 - 652. [Abstract] [Full Text]